Skip to main content

Table 2 Data collection schedule

From: The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics

Parameter

Baseline visit

Follow-up visit

Inclusion/exclusion criteria

×

 

Informed consent, medical records release, and contact order form

×

 

Demographicsa

×

 

Other study participation

×

×

Hypoparathyroidism etiology (primary cause)b

×

 

Family history

×

 

Medical history/condition summary

×

 

Height and weight

×

×

Pregnancy

×

×

Clinical laboratory evaluations

×

×

Other medical proceduresc

×

×

Management of chronic hypoparathyroidism

×

×

rhPTH(1-84) dosing informationd

×

×

Historical PTH dosing informatione

×

 

Prior and concomitant medications, including over-the-counter medications

×

×

Outcome evaluations (socioeconomic status and social history)

×

 

Outcome evaluations (Hypoparathyroidism Symptom Diary, WPAI:SHP, SF-36, SF-10)

×f

×

Other questionnaires (signs and symptoms, hospitalization annual form)

×

×

Vital status database searches

 

×g

Adverse events

×f,h

×

Patient discontinuation

 

×

  1. PTH parathyroid hormone, rhPTH(1-84) recombinant human parathyroid hormone (1-84), SF-10 10-Item Short Form Health Survey questionnaire for pediatric patients, SF-36 36-Item Short Form Health Survey questionnaire for adults, WPAI:SHP Work Productivity and Activity Impairment Specific Health Problem
  2. aFor example, month and year of birth, age
  3. bGenetic mutation, surgery-induced, autoimmune, radiation, idiopathic, other
  4. cFor example, dual-energy x-ray absorptiometry, imaging, bone biopsies
  5. dRefers to the use of rhPTH(1-84) (Natpar®/Natpara®)
  6. eRefers to the use of rhPTH(1-84) (Preotact®) or rhPTH(1-34) (Forteo®)
  7. fDiscrepancy from November 2017 protocol to be corrected in future amendments
  8. gSearch is only performed if patient is a US patient lost to follow-up or reported deceased
  9. hClassification was at investigator discretion after the signing of the informed consent form (ie, adverse events should not be historical events before enrollment)